AffyXell Therapeutics
Seoul
About AffyXell Therapeutics
AffyXell was established in January 2020 by Avacta and Daewoong as a joint venture to develop novel mesenchymal stem cell (MSC) therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $7.2M
- Last round: Corporate Round (Apr 2022)
- Website: affyxell.com
Industries & Categories
Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/affyxell-therapeutics-160657 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.